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Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two apparently 
distinct neurodegenerative diseases, the former characterized by selective loss of motor neurons in 
the brain and spinal cord and the latter characterized by selective atrophy of frontal and temporal 
lobes. Over the years, however, growing evidence from clinical, pathological and genetic findings 
has suggested that ALS and FTD belong to the same clinic-pathological spectrum disorder. This 
concept has been further supported by the identification of the most common genetic cause for 
both diseases, an aberrantly expanded hexanucleotide repeat GGGGCC sequence located in a non-
coding region of the gene C9orf72. Three hypotheses have been proposed to explain how this 
repeats expansion causes diseases: 1) C9orf72 haploinsufficiency-expanded repeats interfere with 
transcription or translation of the gene, leading to decreased expression of C9orf72 protein; 2) 
RNA gain of function-RNA foci formed by sense and antisense transcripts of expanded repeats 
interact and sequester essential RNA binding proteins, causing neurotoxicity; 3) Repeat associated 
non-ATG initiated (RAN) translation of GGGGCC repeat expansion-RAN translation of expanded 
sense and antisense repeats produces potential toxic dipeptide repeat protein (DPR). In this review, 
we assess current evidence supporting or arguing against each proposed mechanism in C9 
ALS/FTD disease pathogenesis. Additionally, controversial findings are also discussed. Lastly, we 
discuss the possibility that the three pathogenic mechanisms are not mutually exclusive and all 
three might be involved in disease.
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1. ALS and FTD: One Clinicopathological Spectrum Disorder
Amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, causes the 
degeneration of upper motor neurons in the cortex and lower motor neurons in the medulla 
and spinal cord. Although few juvenile cases have been reported, ALS has generally an adult 
onset and progresses rather rapidly in most patients (few years from onset to end-stage). 
There are two forms of ALS: sporadic (sALS) and familiar (fALS). About 5% of ALS cases 
are inherited, in which there is a clear family history of disease [1]. In familial ALS cases, an 
autosomal dominant hereditary pattern is usually observed. Since the identification of the 
first causative mutation in SOD1 in 1993, more than 30 genes have been identified to cause 
familial ALS worldwide [2]. These genetic mutations have been found to induce 
disturbances in protein homeostasis, RNA metabolism and/or cause abnormalities in axonal 
structures and functions [2, 3]. ALS involves also non-cell autonomous components, 
meaning cell types other than motor neurons are also affected by the disease pathogenic 
mechanisms and contribute to the demise of the motor neurons.
Frontal temporal dementia (FTD) is second most common form of dementia after 
Alzheimer’s disease in the under 65-age group. As its name implies, FTD is characterized 
by atrophy of the frontal and temporal lobes. Symptoms include changes in personality and 
behaviors, disturbances in language, and cognitive deficits, which worsen progressively [4]. 
Like ALS, there are two types of FTD: familial (fFTD) and sporadic (sFTD). FTD has a 
strong genetic component with up to 50% of the cases being hereditary. Clinical subtypes 
include behavioral variant FTD (bvFTD), progressive non-fluent aphasia (PNFA) and 
progressive aphasia semantic dementia (SD) [5]. The average survival is 8–10 years after 
disease onset [6, 7]. Selective serotonin reuptake inhibitors and serotonin norepinephrine 
reuptake inhibitors have been shown to have positive effects only in some bvFTD patients 
[5]. Over the past twenty years, our understanding of the genetic causes and molecular 
pathogenic mechanisms has been growing at a surprisingly fast pace. Neuropathological 
classification of FTD has also been transformed. Mutations in MAPT (microtubule-
associated protein tau), GRN (progranulin), VCP (AAA-type ATPase valosin-containing 
protein), CHMP2B (charged multiversicular protein 2B), the FET family (DNA/RNA 
binding proteins), including FUS, EWS, and TAF15, have been identified to cause FTD [8]. 
A variety of mechanisms have been implicated in FTD including impairments in 
neurotrophic support, autophagy and proteasome pathways, RNA metabolisms and 
neurofilament structures [7].
Although ALS and FTD present with distinct clinical features, strong associations have been 
found between them. ALS and FTD often occur in the same family and same patients 
sometimes. Indeed, there are overlaps in clinical presentations, genetic causes, pathological 
findings and pathogenic mechanisms. Both diseases are age dependent, and symptoms 
usually start in fifth decade of life. Both diseases relentlessly progress over time, and 
eventually lead to death. More than 50% of sALS patients and 60% of fALS patients have 
cognitive deficits; and around 15% of sALS patients are actually diagnosed with 
concomitant FTD [9, 10]. Similarly, 12.5–14% of FTD patients have concomitant motor 
neuron disease (MND), and another 27–36% of FTD patients have clinical evidence of 
motor system dysfunction [11, 12]. Disease progression seems to be more rapid in FTD 
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patients with concomitant motor neuron disease, as these patients were reported to have an 
earlier onset age and a shorter mean survival [13]. ALS and FTD are not only heterogeneous 
in clinical presentations; they are highly heterogeneous in genetic causes. A number of 
genetic mutations have been found to cause both ALS and FTD, namely mutations in FUS, 
TDP-43, SQSTM1, UBQLN2, CHCHD10, VCP and C9orf72 [14–18]
2. Discovery of GGGGCC/CCCCGG Hexanucleotide Repeat Expansions in 
C9orf72
Multiple groups conducted extensive sequencing in families with hereditary ALS/FTD with 
unknown mutations, and linked the diseases to a 3.7 Mb region in the short arm of 
chromosome 9. Later the region was narrowed down to an 80kb area by genome wide 
association studies (GWAS) [4]. Deep sequencing of exons and exon-intron boundaries 
failed to identify the mutation. However, two independent groups pinpointed the nature and 
location of the mutation by carefully examining non-coding regions and manually aligning 
individual sequences [14, 16].
The mutation turned out to be a vastly expanded GGGGCC repeat (CCCCGG in the 
antisense direction) located in a non-coding region of the C9orf72 gene. Since C9orf72 has 
three different transcript variants, the mutation resides in different regions in different 
variants: Promoter region for variant 2 and first intron for variant 1 and 3.
C9orf72 is located on chromosome 9, in the 72nd open reading frame and consists of 12 
exons. C9orf72 (also referred here as C9) is a highly conserved gene with three transcript 
variants, encoding two protein isoforms. Variants 2 and 3 encode C9orf72 isoform a, the 
longer version with 481 amino acids, and variant 1 encodes C9orf72 isoform b, the shorter 
version containing 222 amino acids. Both isoforms are still of unknown biological function 
(Figure 1).
The most common GGGGCC repeat size in C9orf72 was reported to be 2 in normal, non-
diseased individuals [19]. However, variable ranges of repeat number have been reported for 
controls and patients: fewer than 14 repeats in controls as 20–22 repeats were associated 
with FTD [20]; fewer than 23 repeats in controls [15]; 800–4400 repeats in patients [19]; 0–
30 repeats in controls and more than 500 repeats in patients [21]. And finally a more recent 
study employing a southern blot based semi-automated quantification showed that most 
control carry fewer than 10 repeats, while patients carry 300–3800 repeats [22].
Similar to what was observed in other repeat expansion diseases, the repeat size was also 
found to be associated with sample collection time [22, 23]. C9orf72 repeat expansion sizes 
have been widely reported to vary in different tissue types and cell types [19, 22–24], 
indicating the expansion of repeats might be caused by some cell division-independent 
mechanism in addition to somatic instability. The repeat size variation among different 
tissues within a same carrier was larger than that between different carriers, suggesting that 
intrinsic properties of specific tissue might affect the stability of the expanded repeats. In 
some cases, the difference in size between peripheral blood and CNS tissues was several 
thousand [21, 25]. It was also shown that repeat sizes smaller than 16 were somatically 
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stable, implying higher repeats were prone to expansion [25]. In addition to the repeat size 
variation within the same patient, there are also technical challenges and limited DNA 
available, thus it remains to be answered what is the minimal size for pathogenesis and what 
is the normal range.
3. Disease Mechanisms
Discovery of the expanded GGGGCC repeat in a non-coding region of the C9orf72 gene, the 
most common genetic cause for both ALS and FTD, brought researchers’ attention to a 
group of diseases called repeat expansion disease. Repeat expansions were known to cause a 
number of hereditary diseases, such as fragile X syndrome (FXS), fragile X tremor ataxia 
syndrome (FXTAS), myotonic dystrophy (DM), Huntington’s disease (HD), and 
spinocerebellar ataxia 1 (SCA1) [26]. Three common pathogenic mechanisms underly repeat 
expansion diseases:
1. Loss-of-function, as seen in FXS, where expanded CGG repeats in FMR1 
causes hypermethylation of the promoter region and subsequent loss of 
FMRP protein, which is an essential RNA binding protein that regulates 
local protein synthesis leading to abnormal synaptic function [27];
2. RNA mediated gain-of-function, as seen in DM1, where expanded CTG 
repeats in the gene DMPK form nuclear RNA foci in muscle cells, 
sequester essential RNA binding proteins and causes misregulated RNA 
splicing [28];
3. Protein mediated gain-of-function, as seen in HD, where expanded CAG 
repeats in the coding region of the huntingtin gene are translated into poly-
glutamine (poly-Q) tract, which leads to proteins aggregation and 
disruption of the normal functions of huntingtin [29, 30]. Protein mediated 
gain-of-function can also arise from repeats located in a non-coding 
region, (e.g. intron, 3′UTR, 5′ UTR) where expanded repeats are 
translated into toxic protein through a novel translational mechanism 
called Repeat-Associated Non-ATG initiated (RAN) translation, which 
circumvents the requirement for a canonical start codon [31]. RAN 
translation was first reported in myotonic dystrophy type 1 (DM1) and in 
spinocerebellar ataxia type 8 (SCA8), where expanded CAG•CTG repeats 
in non-coding regions were translated into poly-Gln and poly-Ala [31].
The characteristics of C9orf72 mutation suggest all three potential mechanisms. Here, 
findings in favor of or against each potential mechanism are discussed.
3.1 C9orf72 Haploinsufficiency
C9orf72 expression levels were thoroughly assessed in repeat expansion carriers and control 
population. C9orf72 transcripts were found to be significantly reduced in lymphobast cells, 
frontal cortex, spinal cord, cerebellum and induced pluripotent stem cells (iPSCs) derived 
neurons from patients carrying the repeat expansion, and variant 2 was found to be mostly 
affected [16, 17, 32–36]. In a separate study, variant 2 was identified to be the primary 
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transcript for C9orf72 [37], indicating loss of variant 2 would contribute greatly to loss of 
overall C9orf72 protein levels. Furthermore, higher variant 1 expression levels in frontal 
cortex and cerebellum were found to be survival favorable [32].
Using a customized antibody recognizing both C9orf72 protein isoforms, decreased levels of 
the long isoform were found in patients frontal cortex samples but not in cerebellum samples 
compared to control samples [38]. In another publication, two customized antibodies against 
C9orf72 short and long isoforms respectively were developed, and researchers found that 
C9orf72 long isoform was down regulated in temporal and frontal lobes and no changes 
were detected in cerebellum, motor cortex and lumber spinal cord (low signal) while the 
short isoform was up regulated in C9-ALS patients [39].
However, a case report on a homozygous repeats expansion patient argued against the C9 
loss-of-function (LOF) hypothesis. If C9 LOF were the major disease mechanism, more 
severe clinical course and neuropathological abnormality would be expected in a 
homozygous mutation carrier. In this case, homozygosity of C9 repeat expansion did cause a 
further reduction of C9orf72 transcript levels, but clinical phenotype and neuropathological 
features were not unusual when compared to heterozygous carrier [40].
Do decreased C9orf72 expression levels contribute to disease pathogenesis? To answer this 
question, C9 knockdown or C9 knockout models have been developed. Deletion of alf-1, the 
c. elegans ortholog of C9orf72, led to age-dependent progressive motor deficits similar to 
those seen in TDP-43 and FUS models and increased sensitivity to stress-induced paralysis, 
and GABAergic motor neuron was primarily affected [41]. Similarly, knockdown of 
C9orf72 in zebrafish caused motor deficits and impaired axonal projection [35]. Although c. 
elegans and zebrafish C9 knockdown models suggested loss of C9orf72 was sufficient to 
cause disease phenotype, this hypothesis remained to be further tested since neither C9orf72 
homologs of c. elegans nor zebrafish shared high homology with human C9orf72. Later, a 
series of C9 knockdown and knockout mouse models were generated, where mouse ortholog 
of C9orf72 is highly similar to human C9orf72. Mouse C9orf72 was either conditionally 
removed in neuronal and glial cells using Nestin-Cre system or constitutively removed in all 
cell types using gene targeting or Crispr/Cas9 systems. Heterozygous and homozygous mice 
were analyzed to understand the functional consequences of decreased C9 protein level 
(resembling most of the patients) vs. full knockout of C9 protein. All together, mice with 
decreased or abrogated C9orf72 level failed to show ALS/FTD-like features including motor 
deficits, behavioral abnormality, shortened life span, pathological hallmarks of ALS/FTD 
(TDP-43-positive inclusions, and p62-positive inclusions) [42–47]. To be noted, two C9 
knockout mouse models showed mild motor deficits after 40 weeks [45] and decreased 
survival [47], but these phenotypes were suggested to be caused by other underlying 
conditions rather than ALS/FTD. Using a different approach, C9 level was also successfully 
reduced when antisense oligonucleotides (ASOs) against C9orf72 were injected into adult (8 
week old) mouse intracerebral ventricles, yet no ALS/FTD phenotypes were observed [43]. 
Taken together, absence of ALS/FTD-like phenotypes in C9orf72 knockdown or knockout 
mouse models indicates C9orf72 haploinsufficiency is not the primary cause of ALS/FTD.
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The above C9 knockout mouse models also provide insights into physiological functions of 
C9orf72, albeit they failed to display ALS/FTD related disease phenotypes. Upon close 
examination, these mice showed enlarged spleens and lymph nodes and they also showed 
microglia activation with abnormal lysosomal activity and altered cytokine production, 
suggesting that C9orf72 protein might be involved in regulating immune homeostasis, and 
autophagy/lysosome pathway [44–48]. Surprisingly, neoplastic events were also reported 
seen in one C9 knockout mouse model, which might be triggered by defects in immune 
systems [47].
Understanding the physiological function of C9orf72 is not only important for defining the 
role of C9 haploinsufficiency but also crucial for developing therapeutic strategies to 
mitigate the repeat expansion toxcity. In the hope that knowing where C9orf72 protein is 
located would provide some insight into its functionality, several groups made attempts to 
characterize C9orf72 protein localization in cells, with variable localization profiles 
reported: nuclear [14], primarily cytosolic [49], nuclear and cytoplasmic vesicles [50], 
nuclear, cytosolic and synaptic vesicles [51], and nuclear, P-bodies and stress granules [52]. 
Different cells and tissues were evaluated in these studies. Additionally, various commercial 
antibodies were used, which are still poorly characterized. These differences most likely led 
to different observations. Thus, a more specific antibody is crucial for an accurate 
characterization. Recent studies using customized antibodies provided more information on 
this matter. Using two newly developed antibodies against C9 short or long isoforms, 
researchers demonstrated that C9 long isoform showed diffuse cytoplasmic staining pattern 
and C9 short isoform was found to localize to nuclear membrane [39]. The long isoform of 
the C9orf72 protein also showed distinct speckle-pattern staining only in cytoplasm of 
cerebellar Purkinje neurons-the less affected neuronal cell type in diseases, not in spinal 
motor neurons-the primarily affected cell type [39]. The implications of these interesting 
findings remain to be explored.
Computational algorithms based on sequence and structural similarity predicts that C9orf72 
is a guanine exchange factor with a DENN (Differentially Expressed in Normal and 
Neoplastic) like domain [53]. Consistent with the computational prediction of its function, 
C9orf72 protein was found to colocalize and interact with Rab proteins and was involved in 
endosomal trafficking in cells [50]. The role of C9orf72 protein in autophagy regulation was 
further established in a series of follow up studies: C9orf72 protein was implied in 
regulation of autophagy initiation by functioning as Rab1a effector and interacting with 
ULK1 initiation complex [54]; C9orf72 protein interacted with SMCR8 and WDR41 to 
participate in autophagy initiation [46, 55, 56].
Taken together, C9orf72 haploinsufficiency might not be driving disease pathogenesis, but it 
is highly likely involved in it. It would be of great interest to further characterize the 
function of C9orf72 protein and investigate whether C9orf72 is beneficial in stabilizing 
expanded repeats.
3.2 RNA Gain of Function
Nuclear and cytoplasmic RNA foci formed by sense or anti-sense transcript of the 
GGGGCC repeat expansion were found in C9 patient lymphoblast cells and fibroblast cells. 
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In the CNS, RNA foci were found in glia cells and neurons (more frequently than glia cells) 
of frontal cortex, cerebellum, hippocampus and spinal cord; the RNA foci most likely 
consisted of expanded GGGGCC sequence without flanking regions upstream or 
downstream of the repeat [14, 16, 33, 43, 57–59]. Besides forming RNA foci, the GGGGCC 
repeat expansion was also revealed to form highly stable G-quadruplex structure and R-
loops in vitro [34, 60–62]. G-quadruplex consists of planar stacks formed by four guanine 
residues that are stabilized by Hoogsteen hydrogen bonding (Figure 2A). R-loops are 
hybrids of DNA and RNA formed by nascent RNA strand and template DNA strand during 
transcription [62] (Figure 2B).
Characterization of functional consequences of expanded repeats in C9 patients and their 
iPSC-derived neurons (iPSNs) supported the toxic role of RNA foci. Sequestration of 
ADARB2 protein by RNA foci and altered gene expression profiles were detected in C9 
patient iPSNs and motor cortex; C9-iPSNs’ susceptibility to glutamate toxicity can be 
alleviated by ASOs against C9orf72 accompanied by decreased RNA foci number and 
continuing presence of RAN-DPR (RAN translation product poly-GlyPro level was 
evaluated), suggesting that RNA foci were the primary toxic species [33]. So far, a list of 
RNA binding proteins (RBPs) was identified to co-localize with sense and anti-sense RNA 
foci in patient tissues, including ALYREF, ADARB2, hnRNP-A1, hnRNP-H/F, hnRNP-K, 
hnRNP-U, nucleolin, Pur-α, SC35, SRSF2 [33, 34, 63–66] (summarized in Figure 2C). 
Another group examined the role of G-quadruplex formed by GGGGCC repeats in disease 
pathogenesis. They found that GGGGCC repeat expansion formed G-quadruplex and R-
loops in vitro, which led to aberrant interaction with nucleolar proteins, resulting in 
nucleolar stress, reminiscent of traits seen in C9 patients and their cells, as well as loss of 
full length transcripts and the accumulation of abortive transcripts due to disrupted RNA 
polymerase processivity [34]. To be noted, a different group reported contrary findings that 
the intron containing expanded repeats were transcribed and spliced out correctly in C9 
patients [36]. Overt cellular toxicity, altered RNA processing and nucleolar stress caused by 
expressing GGGGCC repeats in vitro and in vivo lend support to the notion that C9 repeat 
expansion causes disease phenotype through a RNA gain-of-function pathway. A higher 
number of RNA foci in the frontal cortex positively correlated with a younger disease onset 
age in C9 FTD patients, adding further support to RNA toxicity in disease pathogenesis [59].
To explore whether these abundant RNA foci seen in patients would cause 
neurodegeneration, transgenic Drosophila and cell models were developed. When 30 
GGGGCC repeats were cloned into a 5′ UTR, toxicity was observed in vitro in N2a cells, as 
well as decreased locomotor activity and disrupted eye morphology when expressed in 
motor neurons and retinal cells, respectively, in aged flies [67]. In the same study, the 
purine-rich element binding protein A, Pur-α was found to interact with GGGGCC repeats 
and overexpression of Pur-α rescued the degenerative phenotypes. Later, using the same fly 
model, a different group showed expanded GGGGCC transcripts and RNA foci interacted 
with and sequestered the Ran GTPase-activating protein RanGAP, leading to reduced 
nuclear import in vitro and in vivo [68]. Moreover, expression of 38 or longer GGGGCC 
repeats caused apoptosis in neuronal cell lines and fish embryos via sequestration of hnRNP-
H by RNA foci [64]. Besides hnRNP-H, several other translation regulators like eIF2a, FUS 
and ILF3 were also shown to be sequestered into RNA foci leading to translation arrest in 
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cells expressing 31 repeats of GGGGCC [69]. Most of the RBPs sequestered in RNA foci 
would fall into two categories: RNA processing regulators and translation regulators. Gene 
profiling of C9 patient cells and tissues revealed that splicing error rate was associated with 
disease severity, providing support for RBP sequestration by RNA foci as a potential disease 
mechanism [70]. Nevertheless, direct evidence showing functional consequences resulted 
from sequestration of these critical proteins are somewhat lacking. Interestingly, GGGGCC 
repeat RNA particles were also found in neurites of iPSNs from C9 patients, and these 
repeat RNA particles correlated with neuritic arborization defect seen in primary neurons 
expressing expanded repeats and Drosophila carrying 48 GGGGCC repeats (no RAN 
translation product was detected) [71].
And it was suggested that the toxicity might be due to dysfunctional granule transport 
caused by GGGGCC repeat expansion [71]. Contradictory results, however, were also 
reported in several studies where in vitro and in vivo models were used, suggesting RNA 
foci alone were not sufficient to cause neurodegeneration. In a transgenic fly model carrying 
up to 288 pure GGGGCC repeats (RNA only without production of RAN translated 
proteins), neither neurodegeneration nor decreased viability was observed [72]. More 
recently, in another fly model expressing up to 160 GGGGCC repeats with intronic and 
exonic flanking sequences from human C9orf72, which closely resembled the mutation in 
C9 patients, displayed no toxicity when expressed in a variety of tissues. More importantly, 
the average number of sense RNA foci per cell was a lot higher than that in C9 patient iPSCs 
derived neurons [36], suggesting that it was unlikely for RNA foci to be toxic. Similar 
claims have been made from several mouse models. In a mouse model expressing 80 repeats 
of GGGGCC in a 5′-UTR region, the repeat size was proven to remain stable through 
multiple generations and no RAN translation product was detected, however, researchers did 
not find motor/behavior phenotypes, or neuronal cell loss [73]. Moreover, two independently 
generated BAC transgenic mouse models carrying either the full human C9orf72 gene with 
expanded GGGGCC repeats or first six exons of the human C9orf72 gene with expanded 
GGGGCC repeats. These two mouse models both showed formation of abundant sense and 
anti-sense RNA foci as well as Gly-Pro dipeptides similar to pathological findings seen in 
C9 patients, but the mice lived a normal life span without developing any cognitive, 
behavioral or motor defects [74, 75]. In contrast, another two BAC transgenic mouse models 
carrying human C9orf72 gene together with the expanded GGGGCC repeats showed 
ALS/FTD like phenotypes, including cognitive deficits, motor deficits and decreased 
survival [48, 76]. Similarly, these mice also showed pathological and molecular signatures of 
C9 ALS/FTD, including sense and anti-sense RNA foci, and RNA translation products 
(poly-GP, poly-GA and poly-GR inclusions). Moreover, RAN translation was dependent on 
length of repeats, expression levels, age, and disease course [48, 76]. However, it remains 
possible that the observed toxicity could come from RAN translation product.
3.3 RAN Translated Dipeptide Repeat Protein Toxicity
RAN translation of expanded repeats has become an emerging mechanism underlying 
nucleotide repeat disorders since the initial discovery in DM1 and SCA8. Efforts were also 
made to determine whether these unexpected protein products resulted from RAN 
translation would contribute to disease. In fragile X-associated tremor ataxia syndrome 
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(FXTAS), CGG repeats in the 5′ UTR of the fragile X mental retardation gene (FMR1) 
were shown to undergo RAN translation and produce poly-Ala protein and poly-Gly protein 
from different reading frames, the latter of which caused neural toxicity in Drosophila model 
[77] and was shown to trigger impairment in ubiquitin proteasome system (UPS) [78], 
supporting the role of novel protein products from RAN translation in disease pathogenesis. 
Recent progress on how RAN translation occurred in FXTAS provided mechanistic support. 
It was shown that RAN translation of CGG repeats was 30–40% efficient compared to 
canonical translation, and it utilized the canonical translation machinery and was dependent 
on repeat length and surrounding sequence [79].
If both sense and anti-sense transcripts of expanded GGGGCC repeats underwent RAN 
translation, five different dipeptide proteins (DPRs), namely poly-Gly-Ala(GA), poly-Gly-
Pro(GP), poly-Gly-Arg(GR), poly-Pro-Ala(PA), and poly-Pro-Arg(PR), would have been 
produced from different reading frames (Figure 3). In C9 ALS/FTD patient tissues, DPRs 
were initially observed in p62 positive neuronal cytoplasmic inclusions (NCI), which stained 
negatively for the nuclear transcription factor TDP-43 [14, 16, 80–82]. Since their discovery, 
DPR pathology has been a highly consistent and definitive feature for C9orf72 cases. Later, 
the presence of each potential DPR has been described in C9 ALS/FTD patient brain tissues 
and less frequently in spinal cord tissues, using a spectrum of antibodies, targeting either 
specific C-terminal regions or dipeptide-repeat regions of the individual DPRs [57, 58, 83–
87]. DPR inclusions were not limited to neurons, and they were also shown in glial cells [83, 
85, 88, 89]. Most studies reported that individual DPRs shared similar localization patterns 
but displayed different abundances: from highest to lowest are poly-GA, poly-GP, poly-GR, 
and poly-PA/poly-PR [89, 90]. Similar findings were also reported in C9 patient iPSCs 
derived neurons and C9 patient CSF (poly-GP was detected) [33, 49, 91–94]. Fundamental 
questions regarding the role of these C9-DPRs remain: Is the presence of DPRs a mere 
pathological hallmark? Are these DPRs actually causing neurodegeneration?
To clearly dissect the pathogenic mechanisms, researchers used a “random-alternative 
codon” strategy to design DNA constructs encoding each specific DPR or synthetic 
dipeptides, so they could study DPRs independent of one another and from potential 
interference from pure GC sequences at transcript level. Using this approach, GR and PR, 
the two arginine rich DPRs, have been shown to be strongly toxic by multiple groups when 
overexpressed in yeast, cultured neurons and Drosophila, while other DPRs were not or were 
only mildly toxic [49, 72, 95–99]. Interestingly, GR and PR showed distinct localization 
pattern: predominantly nucleolar accompanied by occasional cytoplasmic localization. 
Further analysis revealed that these arginine rich DPRs interact with a number of nucleolar/
nuclear proteins and cause global translational dysregulations, including induction of 
nucleolar stress, suppression of rRNA synthesis, abnormal stress granule formation, splicing 
aberration, and inhibition of protein translation [49, 95, 96, 100]. Several cellular pathways 
have also been reported as potential disease mechanisms: Dysfunction of UPS [101]; 
Disturbance in nucleocytoplasmic transport [99, 102]; Suppression of Notch signaling 
pathway [98]. Surprisingly, co-expression of GA was found to partially mitigate toxicity 
caused by GR in Drosophila cells and human iPSNs [98]. In addition, Drosophila carrying 
160 intronic GGGGCC repeats showed abundant RNA foci but no neurodegeneration when 
grown at 25°C, while Drosophila expressing 36 GGGGCC repeats with a poly(A) tail, which 
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readily produced GR and GP, displayed neurodegeneration phenotype [36]. More 
interestingly, when grown at a higher temperature, decreased survival was observed in 
Drosophila carrying 160 intronic GGGGCC repeats, which correlated with the production of 
GR, lending further support to the theory that R-rich DPRs induce neurotoxicity [36].
Tandem repeats of Gly-Ala is characteristic of EBNA1 protein of Ebstein-Barr virus and has 
been shown to impair proteasome functions [103, 104]. Likewise, studies showed that 
overexpression of poly-GA in cultured cells induced sequestration of Unc119, inhibition of 
proteasome activity, endoplasmic reticulum (ER) stress, reduced dendritic branching 
complexity, and apoptosis; Overexpression of Unc119 or inhibitors of ER stress ameliorated 
toxicity caused by GA expression [105, 106]. Another study showed that overexpression of 
GA or GP caused cellular toxicity via disrupting the UPS [101]. More intriguingly, 15 
repeats of GA dipeptides were shown to form toxic amyloid fibrils when incubated in test 
tubes and could be transmitted from cell to cell [107]. However, it remains to be tested 
whether GA would spontaneously form amyloid fibrils when expressed in cells. Recently, 
mice expressing GA dipeptides were generated using a viral delivery system by injecting 
AAV1 encoding GFP tagged 50 repeats of GA into intracerebral ventricles [108]. These 
mice showed brain atrophy, motor deficits, and behavioral abnormality indicative of 
ALS/FTD like symptoms, confirming that expression of GA causes neurotoxicity in vivo. 
Consistent with the previous study, 50 repeats of GA dipeptides were found to form toxic 
fibrils, and the toxicity was conformation dependent since disruption of fibril formation 
would abolish toxicity. Furthermore, sequestration of HR23 proteins and nuclear pore 
proteins by GA aggregates were implied as potential mechanisms. It is of notice that each 
research group employed a unique sequence with different combination of alternative 
codons, different G/C content and different levels of repetitive sequences to encode the same 
DPR. These differences might lead to varied expression levels of the same DPR species and 
other unknown effects, which might explain the inconsistency in DPR toxicity seen by 
different groups.
In summary, overexpression of arginine rich DPRs cause neurotoxicity in vitro and in vivo 
by disturbing global translational regulation, nucleocytoplasmic transport, UPS, and by 
suppressing Notch signaling pathway; whether other DPRs cause direct neurotoxicity 
remains conflicting. Nevertheless, expression of C9-RAN DPR (GA) alone is sufficient to 
cause neurodegenerative phenotypes in vivo, strengthening the role of DPR toxicity in 
disease pathogenesis (summarized in Figure 3).
How relevant is DPR toxicity to human diseases remains debatable. If DPR toxicity causes 
direct neurodegeneration in disease, one would intuitively expect to see an overall heavier 
DPR burden or more toxic DPR species in regions or cell types that are affected most in the 
disease, or correlation between DPR pathology load and disease severity. The main 
argument is that there is low abundance of DPRs in key regions, and DPR distribution 
patterns and abundances do not differ between disease types (ALS vs. FTLD), nor do they 
correlate with disease onset, neurodegeneration, or phenotype [85, 89, 90, 109]. Exceptions 
were also reported in a few studies. In one study, the poly-GA positive dystrophic neurites 
were found associated with frontal cortex degeneration in FTLD and total poly-GA loads 
were associated with disease onset [90]. Cerebellar poly-GP levels were significantly lower 
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in ALS patient samples compared to FTLD and FTLD-MND patient samples and was also 
associated with cognitive deficits [110]. Although poly-PR inclusions were rare, the total 
burden was shown to be significantly higher in CA3/4 regions in FTLD cases than MND 
cases [89]. Moreover, the lack of abundant DPRs pathology, especially toxic arginine rich 
DPRs, in patient post-mortem tissues could also be explained by the possibility that toxic 
DPRs caused neuronal death, thus neurons “survived” and showed up in pathology tissue 
sections were those who did not have abundant DPRs. So, non-invasive or minimally 
invasive assays that could detect R-rich DPRs in patients throughout disease course would 
provide invaluable information. Interestingly, pathological findings from three C9orf72-
FTLD patients who prematurely died shortly after disease onset suggested that DPRs were 
abundant throughout the cerebral cortical regions, hippocampus, and cerebellum, while 
TDP-43 pathological changes were sparse [111].
Additionally, some studies state that TDP-43 cytoplasmic inclusions were more abundant 
than DPRs, and that the occurrence of TDP-43 correlates to degeneration in specific areas in 
C9ORF72-positive patients [85, 109]. However, a recent systematic review of a large cohort 
of pathological studies looking at TDP-43, p62, and DPR inclusions in the brains and spinal 
cords of C9ORF72-positive patients reported different findings [112]. A total of 261 
C9orf72-positive patients were analyzed after excluding studies that only looked at one type 
of inclusion or one specific CNS region, and it was shown that there was greatly lower 
prevalence of TDP-43 inclusions in the cerebellum and hippocampus than DPRs and p62. 
Additionally, there was little to no difference between the prevalence of TDP-43, DPRs, and 
p62 inclusions in the frontal lobe, temporal lobe, spinal cord, and brainstem [112].
4. Concluding Remarks
Despite the excitement of identifying C9orf72 mutation as the most common genetic cause 
for ALS and FTD, we need to acknowledge that it is critical and challenging to decipher 
how the enormously expanded GGGGCC repeats in a non-coding region of C9orf72 gene 
cause neurodegeneration. Three pathogenic mechanisms were proposed. The research field 
of C9orf72 has been moving at a fast pace to determine which mechanism induce 
neurotoxicity and benefited greatly from lessons learned from other repeat expansion 
diseases. Abundant pathological and experimental findings have emerged. It remains to be 
investigated which pathogenic mechanism strikes neurons first and if there is a sequential 
cascade of neurotoxic events. Successful development of targeted therapeutics also relies on 
defining the contribution of each pathogenic mechanism.
Recent development of several lines of BAC transgenic mice carrying partial or full human 
C9orf72 gene and expanded GGGGCC repeats has greatly advanced modeling of the 
diseases in rodents. What is more intriguing is the discrepancy of phenotypes of different 
lines-some of the lines showed ALS/FTD like phenotypes [48, 76] while others did not show 
any phenotypes [74, 75]. For the line that showed more robust phenotypes, one obvious 
difference is the different strain background-FVB/NJ was used in this line as opposed to 
C57BL/6 or SJL/B6 in other lines. The mutation specific for one genetic strain has led to the 
discovery of novel functions of GTPBP2 and potentials of mutations in tRNAs in causing 
neurodegeneration [113]. Although the reasons for the discordant results are complicated 
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and still unknown, there is a possibility that the different genetic background could be one 
underlying cause like in the case. A thorough comparison of different lines would provide 
more mechanistic insights.
Keeping in mind that these pathogenic mechanisms are not mutually exclusive, one should 
also explore the consequences of two or more mechanisms co-existing in the same model, 
e.g. crossing the BAC mouse with the C9 knockout mouse. It is possible that one mechanism 
might protect neurons against the toxicity caused by other mechanism(s). It is also possible 
that one mechanism might enhance the toxicity induced by other mechanism(s). There might 
also be convergence of mechanisms. Indeed, loss of C9orf72 protein sensitized cells to 
toxicity induced by expression of 30 repeats and 60 repeats of GGGGCC [52]. Moreover, 
decreased level of C9orf72 short isoform nuclear membrane staining has been found in C9-
ALS patients, and the short isoform of the C9orf72 protein has also been found to physically 
interact with importin-b and RAN-GTPase [39]. Disruption of nucleocytoplasmic transport 
was associated with RNA toxicity as well as protein toxicity from R-rich DPRs [68, 97, 99]. 
Although it is premature to say C9 loss-of-function induce neurodegeneration together with 
toxic RNA and DPRs via disruption of nuclear transport, it is definitely worth further 
exploration.
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Figure 1. The three C9orf72 transcripts and GGGGCC hexanuleotide repeat expansion
Three C9 transcript variants and two C9 protein isoforms are listed and named as in 
PubMed. GGGGCC hexanucleotide repeat (blue hexagon) and exons (brown block) are 
indicated. Predicted molecular weight for each protein isoform is listed.
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Figure 2. GGGGCC/CCCCGG repeat expansions form G quadruplex and R-loops and interact 
with RBPs
(A) Four guanine residues (pink ball) form a G-quartet through eight pairs of hoogsteen 
hydrogen bonding. G-quartets stack on top of each other, forming helical G-quadruplex 
structure. (B) R-loops are formed newly transcribed RNA transcript and unwound DNA 
template during transcription. (C) A summary of RBPs reported to be sequestered in RNA 
foci or to interact with GGGGCC or CCCCGG RNA repeats.
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Figure 3. RAN translated DPRs impair cellular functions
RAN translation of sense and anti-sense transcripts of expanded GGGGCC repeats in all 
possible reading frames gives rise to five DPRs. Sense strand: poly-GA, poly-GP and poly-
GR. Anti-sense strand: poly-PA, poly-PR and poly-GP (same as sense strand). Impairments 
in multiple cellular functions are found caused by C9-DPRs.
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